Ursprung des Netzwerks ersten Grades von Kim Nearing
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
MaveriX Oncology, Inc.
MaveriX Oncology, Inc. BiotechnologyHealth Technology MaveriX Oncology, Inc. operates as a a biotechnology company. It focuses on the discovery, development, and commercialization of targeted small molecule cancer chemo-immunotherapies. The company was founded by Steven A. Everett and Craig Alan Coburn in 2015 and is headquartered in Palo Alto, CA.
3
| Holding Company | Biotechnology | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Kim Nearing
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Spear Therapeutics Ltd.
Spear Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Spear Therapeutics Ltd. develops cancer treatment drugs. The firm offers cytochrome P450 (CYP)-activated prodrugs. It designs prodrugs that are activated by enzymes that are found in cancer tissues. The company was founded by Steven A. Everett and Gerard Andrew Potter and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Founder | |
The University of California, San Francisco | College/University | Corporate Officer/Principal | |
University Of Dundee | College/University | Corporate Officer/Principal | |
University of Ulster | College/University | Undergraduate Degree | |
Brunel University | College/University | Masters Business Admin | |
Q BIOMED INC. | Pharmaceuticals: Major | Director/Board Member | |
University of Toronto | College/University | Doctorate Degree | |
Wuxi Apptec, Inc.
Wuxi Apptec, Inc. Data Processing ServicesTechnology Services Wuxi Apptec, Inc. provides pharmaceutical and biotechnology services. Its services include discovery, lab testing division, small molecule pharmaceutical development and manufacturing international discovery service unit, WuXi biologics, chemistry, bioanalytical, clinical & regulatory, genome center, biological reagents and WuXi venture fund. The company was founded by Ge Li in December 2000 and is headquartered in St. Paul, MN. | Data Processing Services | Corporate Officer/Principal | |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Calcilytix Therapeutics, Inc. | Corporate Officer/Principal | ||
VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Corporate Officer/Principal | |
McMaster University | College/University | Undergraduate Degree | |
NRX PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
BridgeBio Pharma LLC
BridgeBio Pharma LLC BiotechnologyHealth Technology BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA. | Biotechnology | Corporate Officer/Principal |
Statistik
International
Vereinigte Staaten | 11 |
Vereinigtes Königreich | 5 |
Kanada | 3 |
Sektoral
Health Technology | 9 |
Consumer Services | 7 |
Technology Services | 2 |
Operativ
Corporate Officer/Principal | 10 |
Director/Board Member | 5 |
Founder | 3 |
Chief Executive Officer | 2 |
Chief Tech/Sci/R&D Officer | 2 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Rick Panicucci | 11 |
Steven A. Everett | 7 |
Norbert Prenzel | 1 |
- Börse
- Insiders
- Kim Nearing
- Unternehmensverbindungen